Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 12/20 | 1.00 |
| ▸ | KDR | P35968 | 11/20 | 1.00 |
| ▸ | FYN | P06241 | 2/20 | 0.70 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17620614 | 0.93 | PDGFRB (0.86) | PDGFRBKDRFYNSIRT5 | |
| SCHEMBL17620625 | 0.92 | PDGFRB (1.00) | PDGFRBKDRFYNSIRT5 | |
| SCHEMBL17620623 | 0.88 | PDGFRB (1.00) | PDGFRBKDRFYNSIRT5 | |
| SCHEMBL17635124 | 0.86 | PDGFRB (1.00) | PDGFRBKDRFYNSIRT5 | |
| SCHEMBL17620611 | 0.86 | KDR (1.00) | PDGFRBKDRFYNSIRT5 | |
| SCHEMBL17620619 | 0.83 | PDGFRB (1.00) | PDGFRBKDRFYNSIRT5 | |
| SCHEMBL17620631 | 0.83 | PDGFRB (1.00) | PDGFRBKDRFYNSIRT5 | |
| SCHEMBL18613299 | 0.82 | FYN (1.00) | PDGFRBKDRFYNSIRT5 | |
| SCHEMBL30521898 | 0.82 | FYN (1.00) | PDGFRBKDRFYNSIRT5 | |
| SCHEMBL17620608 | 0.82 | PDGFRB (0.84) | PDGFRBKDRFYNSIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160102088-A1 | PIPERIDYLPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASE INHIBITORS AND OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 | ALLERGAN, INC. | 2016-04-14 | — | — | US | disclosed |
| US-20160102088-A1 | PIPERIDYLPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASE INHIBITORS AND OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 | ALLERGAN, INC. | 2016-04-14 | — | — | US | disclosed |
| US-9296747-B1 | Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2 | ALLERGAN, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296747-B1 | Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2 | ALLERGAN, INC. (US) | 2016-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102088-A1 | PIPERIDYLPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASE INHIBITORS AND OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 | KDR, PTGFR, TEK | PDGFRB 5/4885KDR 1/4885FYN 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.